Targeted therapy for nonsmall cell lung cancer: Focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors

Anti-Cancer Drugs

Volumn 21, Issue 2, 2010, Pages 151-168

  Kotteas, Elias A ^a   Charpidou, Andriani G ^a   Syrigos, Kostas N ^a,b  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Epidermal growth factor receptor; Nonsmall cell lung cancer; Targeted therapy

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EJB 569; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MATUZUMAB; NAVELBINE; PACLITAXEL; PANITUMUMAB; PELITINIB; PERTUZUMAB; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; SORAFENIB; SUNITINIB; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ACNE; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ARTERIOSCLEROSIS; ASTHENIA; ATAXIA; BLEEDING; BLOOD ROXICITY; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM BLEEDING; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INSOMNIA; KIDNEY CARCINOMA; LEUKOENCEPHALOPATHY; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MENTAL INSTABILITY; METASTASIS; MORNING SICKNESS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QT PROLONGATION; REVIEW; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMOLISM; THYROID TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 76149130390     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328334da02     Document Type: Review

References (185)

1. Werner-Wasik M, Solan M. Clinical prognostic factors in non-small cell lung cancer. In: Syrigos KN, Nutting C, Roussos C, editors. Tumors of the chest, biology, diagnosis and management. New York: Springer; 2006. pp. 177-187.
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-18.
3. Folkman J. What is evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6.
4. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3:401-410.
5. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology 2004; 19:176-182.
6. Cox G, Jones JL, Walker R, Steward WP, O'Byrne KJ. Angiogenesis and non-small cell lung cancer. Lung Cancer 2000; 27:81-100.
7. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219:983-985.
8. Breen EC. VEGF in biological control. J Cell Biochem 2007; 102:1358-1367.
9. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/ vascular endothelial growth factor, microvascular hypermeability and angiogenesis. Am J Pathol 1995; 146:1029-1039.
10. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005; 2:193-200.
11. Shimanuki Y, Tagahashi K, Cui R, Hori S, Takahashi F, Miyamoto H, et al. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 2005; 183:29-42.
12. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996; 73:931-934.
13. Fontanini G, Vignati S, Boldrin L, Chinè S, Silvestri V, Lucchi M, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell carcinoma. Clin Cancer Res 1997; 3:861-865.
14. Baillie R, Carlile J, Pendleton N, Schor AM. Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer. J Clin Pathol 2000; 54:116-120.
15. Ohta Y, Tanaka Y,Watanabe G, Minato H. Predicting recurrence following curative surgery in stage I non-small cell lung cancer patients using an angiogenesis-associated factor. J Exp Clin Cancer Res 2007; 26:301-305.
16. Chakra M, Pujol JL, Lamy PJ, Bozonnat M, Quantin X, Jacot W, et al. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J Thorac Oncol 2008; 3:1119-1126.
17. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2004; 22:2184-2191.
18. Sandler A, Gray R, Perry MC, Brahme J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550. (Pubitemid 44917502)
19. Reck M, Von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-1234.
20. Sandler AB, Johnson DH, Brahmer J, Schiller JH, Ostland M, Gray R, et al. A study of clinical and radiographic risk factors associated with early onset severe pulmonary hemorrhage in bevacizumab (Avastin) treated patients with advanced non-small cell lung cancer [abstr 8074]. J Clin Oncol 2008; 26 (Suppl).
21. Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, et al. Phase II study of pemetrexed and carboplatin with maintenance pemetrexed and bevacizumab as first-line therapy for for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2009; 27:3284-3289.
22. Akerley WL, Langer CJ, Oh D, Strickland DK, Joo S, Xia Q, et al. Acceptable safety of bevacizumab in patients with brain metastases due to non-small cell lung cancer [abstr 8043]. J Clin Oncol 2008; 26 (Suppl).
23. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009; 27:5255-5261.
24. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005; 11:6966-6971.
25. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, et al. Regression of established tumor metastasis by potent vascular endothelial growth factor blocade. Proc Natl Acad Sci U S A 2003; 100:7785-7790.
26. Massarelli E, Miller VA, Leighl NB, Rosen PJ, Albain KS, Hart LL, et al. Phase II study of the efficacy and safety of intravenous (i.v) AVE0005 (VEGF Trap) given every 2 weeks in patients (pts) with platinum-and erlotinib-resistant adenocarcinoma of the lung (NSCLC). J Clin Oncol 2007; 25 (Suppl):S18.
27. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91 (Suppl):S4082-S4085.
28. Minchinton AI, Fryer KH, Wendt KR, Clow KA, Hayes MM. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996; 7:339-343.
29. Miller AA, Case D, Atkins JN, Giguere JK, Bearden JD. Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer. J Thorac Oncol 2006; 1:832-836. (Pubitemid 47181389)
30. Lee SM, Rudd RM, Woll PJ, Ottensmeier CH, Gilligan D, Price A, et al. Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:5248-5254.
31. Schiller JH, Dahlberg SE, Mehta M, Johnson DH. A phase III trial of carboplatin, paclitaxel, and thoracic radiation therapy with or without thalidomide in patients with stage III non-small cell carcinoma of the lung (NSCLC): E3598. J Clin Oncol 2009; 27 (Suppl):S15.
32. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999; 18:4414-4423.
33. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285.
34. Abdollahi A, Hahnfeldt P, Maercker C, Gröne HJ, Debus J, Ansorge W, et al. Endostatin's antiangiogenic signaling network. Moll Cell 2004; 13:649-663.
35. Whitworth A. Endostatin: are we waiting for godot? J Natl Cancer Inst 2006; 98:731-733.
36. Sun Y,Wang J, Liu Y, Song X, Zhang Y, Li K, et al. Results of phase III trial of EndostarTM (rh-endostatin, YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2005; 23 (Suppl):S16.
37. Yarden Y. The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37 (Suppl):S3-S8.
38. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001; 2:127-137.
39. Artaega CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003; 284:122-130.
40. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984; 307:521-527.
41. Xu YH, Richert N, Ito S, Merlino GT, Pastan I. Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci U S A 1984; 81:7308-7312.
42. Baselga J, Averbuch SD. ZD1839 (Iressa) as an anticancer agent. Drugs 2000; 60 (Suppl):S33-S40.
43. Sirotnak FM. Studies with ZD1839 in preclinical models. Semin Oncol 2003; 30 (Suppl):S12-S20.
44. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumour xenografts is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6:4885-4892.
45. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
46. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
47. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, Von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-1537.
48. Giaccone G, Herbst RS, Manelgold C, Scagliotti G, Rosell R, Mille V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22:777-784. (Pubitemid 41103588)
49. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22:785-794. (Pubitemid 41103589)
50. Chang A, Parikh P, Thongprasert S, Tan EH, Perng RP, Ganzon D, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006; 1:847-855.
51. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23:8081-8092.
52. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III placebo controlled study in advanced non-small cell lung cancer. J Clin Oncol 2006; 24:5034-5042.
53. Giaccone G, Iacona RB, Fandi A, Janas M, Ochs JS, Herbst RS, et al. Epidermal growth factor receptor expression analysis in chemotherapynaive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. J Cancer Res Clin Oncol 2009; 135:467-476.
54. Cappuzzo F, Ligorio C, Jänne PA, Toschi L, Rossi E, Trisolini R, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007; 25:2248-2255.
55. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007; 18:752-760. (Pubitemid 46523281)
56. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with nonsmall cell lung cancer. Clin Cancer Res 2005; 11:3750-3757.
57. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23:2493-2501.
58. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23:2513-2520.
59. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008; 26:4244-4252.
60. Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006; 95:998-1004.
61. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24:3340-3346.
62. Mok TS,Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957.
63. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372:1809-1818.
64. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57:4838-4848.
65. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267-3279.
66. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132.
67. Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, Seymour L, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006; 7:389-394.
68. Wacker B, Nagrani T,Weinberg J,Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13:3913-3921.
69. Spigel DR, Lin M, O'Neill V, Hainsworth JD. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer 2008; 112:2749-2755.
70. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE a phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2005; 23:5892-5899.
71. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25:1545-1552.
72. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer -molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133-144.
73. Zhu CQ, Da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26:4268-4275.
74. Hirsch FR, Varella-Garcia M, Dziadziuszko R, Xiao Y, Gajapathy S, Skokan M, et al. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res 2008; 14:6317-6323.
75. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23:5900-5909.
76. Gandara DR, Gumerlock PH. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J Clin Oncol 2005; 23:5856-5858.
77. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinumbased chemotherapy in patients with advanced NSCLC. J Clin Oncol 2009; 27 (Suppl):S15.
78. Massuti B, Moran T, Porta R, Queralt C, Cardenal F, Mayo C, et al. Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: final results of the Spanish Lung Cancer Group (SLCG) trial. J Clin Oncol 2009; 27 (Suppl):S15.
79. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small cell lung carcinoma: a review. Clin Lung Cancer 2006; 8:30-38.
80. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib and erlotinib. PLoS Med 2006; 2:17.
81. Han SW, Kim TY, Hwang PG, Hwang PG, Im SA, Lee KH, et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combinibg analysis of epidermal growth factor mutation, k-ras mutation and Akt phosphorylation. Clin Cancer Res 2006; 12:2538-2544.
82. Miller VA, Zakowski M, Riley GJ, Pao W, Ladanyi AS, Tsao A, et al. EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchoalveolar cell carcinoma (BAC): results from a prospective phase II trial [abstr 7003]. J Clin Oncol 2006; 24 (Suppl):364s.
83. Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas G, et al. Biomarker analyses from the phase III placebocontrolled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. J Clin Oncol 2009; 27 (Suppl):S15.
84. Janne PA. Challenges of detecting EGFR T790M in gefitinib/ erlotinibresistant tumors. Lung Cancer 2008; 60 (Suppl):S3-S9.
85. Zucali PA, Ruiz MG, Giovannetti E, Destro A, Varella-Garcia M, Floor K, et al. Role of cMET expression in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008; 19:1605-1612.
86. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Cancer Res 2003; 9:2316-2326.
87. Guix M, Faber AC,Wang SE, Olivares MG, Song Y, Qu S, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118:2609-2619.
88. Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008; 14:7060-7067.
89. Lee DH, Kim SW, Suh C, Yoon DH, Yi EJ, Lee JS. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol 2008; 19:2039-2042.
90. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowsk T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733-2743.
91. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16:1647-1655.
92. Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung. Br J Cancer 2002; 86:1449-1456.
93. Tan D, Deeb G,Wang J, Slocum HK,Winston J,Wiseman S, et al. HER-2/ neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn Mol Pathol 2003; 12:201-211.
94. Kuyama S, Hotta K, Tabata M, Segawa Y, Fujiwara Y, Takigawa N, et al. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol 2008; 3:477-482.
95. Smylie M, Blumenschein GR, Dowlati A, Garst J, Shepherd FA, Rigas JR, et al. A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history. J Clin Oncol 2007; 25 (Suppl):S18.
96. Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, Gallagher KT, et al. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Cancer Res 2008; 68:571-579.
97. Rabindran SK, Discafani CM, Rosfjord EC, Rosfjord EC, Baxter M, Floyd MB, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004; 64:3958-3965.
98. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005; 102:7665-7670.
99. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008; 105:2070-2075.
100. Besse B, Eaton KD, Soria JC, Lynch TJ, Miller V,Wong KK, et al. Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer. Presented at the 20th Annual EORTC-NCI-AACR Symposium, Geneva, Switzerland, 2008.
101. Calvo E, Tolcher AW, Hammond LA, Patnaik A, De Bono JS, Eiseman IA, et al. Administration of CI-1033, an irreversible pan-ErbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study. Clin Cancer Res 2004; 10:7112-7120.
102. Jänne PA, Von Pawel J, Cohen RB, Crino L, Butts CA, Olson SS, et al. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated non small-cell lung cancer. J Clin Oncol 2007; 25:3936-3944.
103. Erlichman C, Hidalgo M, Boni JP, Martins P, Quinn SE, Zacharchuk C, et al. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2006; 24:2252-2260.
104. Discafani CM, Carroll ML, Floyd MB, Hollander IJ, Husain Z, Johnson BD, et al. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2- butynamide (CL-387,785). Biochem Pharmacol 1999; 57:917-925.
105. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW 2992 an irreversible EGFR/HER2 inhibitor effective in preclinical lung cancer models. Oncogene 2008; 27:4702-4711.
106. Minkovsky N, Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Invest Drugs 2008; 9:1336-1346.
107. Shih J, Yang C, Su W, Hsia T, Tsai C, Chen Y, et al. A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2). J Clin Oncol 2009; 27 (Suppl):S15.
108. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67:11924-11932.
109. Janne A, Reckamp K, Koczywas M, Engelman JA, Camidge DR, Rajan A, et al. Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): a two-arm, phase II trial. J Clin Oncol 2009; 27 (Suppl):S15.
110. Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007; 25:5777-5784.
111. Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small cell lung cancer. Ann Oncol 2008; 19:362-369.
112. Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer 2008; 113:2512-2517.
113. Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:9089-9096.
114. Thienelt CD, Bunn PA Jr, Hanna N, Rosenberg A, Needle MN, Long ME, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005; 23:8786-8793.
115. Herbst RS, Chansky K, Kelly K, Atkins JN, Davies AM, Dakhil SR, et al. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. J Clin Oncol 2007; 25 (Suppl):S18.
116. Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Jänne PA, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006; 24:5253-5258.
117. Pirker R, Pereira JR, Szczesna A, Von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-smallcell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373:1497-1498.
118. O'Byrne KJ, Bondarenko I, Barrios C, Eschbach C, Martens U, Hotko Y, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study. J Clin Oncol 2009; 27 (Suppl):S15.
119. Pujol J, Lynch TJ, Rosell R, Butts CA, Shepherd FA, Thatcher N, et al. A meta-analysis of four randomized phase II/III trials adding cetuximab to platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC). Presented at the 34th ESMO Multidisciplinary Congress, 2009, abstract 9005.
120. Shepherd FA. Targeted therapy in the management of lung cancer. Is there more hype than hope? Targ Oncol 2008; 3:131-133.
121. Olsen CC, Paulus R, Komaki R, Varella-Garcia M, Dziadziuszko R, Curran WJ, et al. RTOG 0324: a phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients with stage IIIA/B non-small cell lung cancer (NSCLC)-Association between EGFR gene copy number and patients' outcome [abstr 7606]. J Clin Oncol 2008; 26 (Suppl).
122. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008; 26:3351-3357.
123. De Castro-Carpeno J, Belda-Iniesta C, Casado Saenz E, Hernandez Agudo E, Feliu Battle J, Gonzalez Baron M, et al. EGFR and colon cancer: a clinical review. Clin Transl Oncol 2008; 10:6-13.
124. Khambata-Ford S, Harbison C, Woytowitz D, Awad M, Horak C, Xu LA, et al. K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: retrospective analyses of the BMS099 trial. J Clin Oncol 2009; 27 (Suppl):S15.
125. Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 2007; 18:7-15.
126. Crawford J, Sandler AB, Hammond LA, Schiller J, Belani C, Kozloff M, et al. ABXEGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC) [abstr 7083]. J Clin Oncol 2004; 22 (Suppl).
127. Socinski MA. Antibodies to the epidermal growth factor receptor in non-small cell lung cancer: current status of matuzumab and panitumumab. Clin Cancer Res 2007; 13:4597-4601.
128. Kim T. Technology evaluation: matuzumab, Merck KgaA. Curr Opin Mol Ther 2004; 6:96-103.
129. Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, et al. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non small-cell lung cancer. Ann Oncol 2006; 17:1007-1013.
130. Charpidou A, Blatza D, Anagnostou V, Syrigos KN. Review. EGFR mutations in non-small cell lung cancer-clinical implications. In vivo 2008; 22:529-536.
131. Kute T, Lack CM,Willingham M, Bishwokama B,Williams H, Barret K, et al. Development of herceptin resistance in breast cancer cells. Cytometry 2004; 57:86-93.
132. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6:117-127.
133. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J, et al. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61:4744-4749.
134. Albanell J, Codony J, Rovira A, Mellado B, Gascón P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003; 532:253-268.
135. Lara PN Jr, Laptalo L, Longmate J, Lau DH, Gandour-Edwards R, Gumerlock PH, et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium Screening and phase II trial. Clin Lung Cancer 2004; 5:231-236. (Pubitemid 38312739)
136. Clamon G, Herndon J, Kern J, Govindan R, Garst J,Watson D, et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer 2005; 103:1670-1675.
137. Krug LM, Miller VA, Patel J, Crapanzano J, Azzoli CG, Gomez J, et al. Randomized phase II study of docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung cancinoma. Cancer 2005; 104:2149-2155.
138. Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 2004; 22:1180-1187.
139. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab un HER2-positive non-small-cell lung cancer. Ann Oncol 2004; 15:19-27. (Pubitemid 38139598)
140. Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 2004; 44:99-110.
141. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinoma. Cancer Res 2005; 65:1642-1646.
142. Swanton C, Futreal A, Eisen T. Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res 2006; 12:4377-4383.
143. Portera CC, Walshe JM, Rosing DR, Denduluri N, Berman AW, Vatas U, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008; 14:2710-2716.
144. Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006; 24:4324-4332.
145. Johnson BE, Jänne PA. Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cancer. Clin Cancer Res 2006; 12:4436-4440.
146. Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 2007; 13:6175-6181.
147. Friess T, Scheuer W, Hasmann M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005; 11:5300-5309.
148. Papaetis GS, Roussos C, Syrigos KN. Targeted therapies for non-small cell lung cancer. Curr Pharm Des 2007; 13:2810-2831.
149. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetics and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24:16-24.
150. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26:650-656.
151. Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer J, Atkins J, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009; 101:1543-1548.
152. Blumenschein GR, Gatzemeier U, Fosella F, Stewart DJ, Cupit L, Gihon F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:4274-4280.
153. Gutierrez M, Kummar S, Allen D, Turkbey B, Choyke P, Wright JJ, et al. A phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (NSCLC) [abstr 19084]. J Clin Oncol 2008; 26 (Suppl).
154. Schiller JH, Lee JW, Hanna NH, Traynor AM, Carbone DP. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501 [abstr 8014]. J Clin Oncol 2008; 26 (Suppl).
155. Hanna N, Von Pawel J, Reck M, Scagliotti G. Carboplatin/paclitaxel with/without sorafenib in chemonaive patients with stage IIIB-IV non-small-cell lung cancer: interim analysis results from a randomized phase III trial (ESCAPE). J Thorac Oncol 2008; 3 (Suppl):S268.
156. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62:4645-4655.
157. Tonra JR, Deevi DS, Corcoran E, Li H, Wang S, Carrick FE, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006; 12:2197-2207.
158. Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capo A, et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study. J Clin Oncol 2009; 27:2523-2529.
159. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). J Clin Oncol 2009; 27 (Suppl):S15.
160. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007; 25:4270-4277.
161. Hanrahan EO, Heymach JV. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res 2007; 13:4617-4622.
162. Herbst RS, Sun Y, Korfee S, Germonpre P, Saijo N, Zhou C, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). J Clin Oncol 2009; 27 (Suppl):S18.
163. De Boer R, Arrieta O, Gottfried M, Blackhall FH, Raats J, Yang CH, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). J Clin Oncol 2009; 27 (Suppl):S15.
164. Gauler TC, Besse B, Meric JB, Gounant V, Fischer T, Overbeck T, et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1250mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25 (Suppl):S18.
165. Laurie SA, Gauthier I, Arnold A, Shepherd FA, Ellis PM, Chen E, et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008; 26:1871-1878.
166. Gadgeel SM, Wozniak A, Edelman MJ, Valdivieso M, Heilbrun L, Venkatramanamoorthy R, et al. Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC) [abstr 19007]. J Clin Oncol 2009; 27 (Suppl).
167. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68:4774-4782.
168. Von Pawel J, Kaiser R, Eschbach M, Stefanic M, Love J, Gatzemeier U, et al. A double blind phase II study of BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25 (Suppl):S18.
169. Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W, et al. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res 2007; 13:3713-3723.
170. Rizvi NA, Kris MG, Miller VA, Krug LM, Bekele S, Dowlati A, et al. Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: results from phase II [abstr 8053]. J Clin Oncol 2008; 26 (Suppl).
171. Miller VA, Wakelee HA, Lara PN, Cho J, Chowhan NM, Costa D, et al. Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: preliminary results of a phase II trial [abstr 8028]. J Clin Oncol 2008; 26 (Suppl).
172. De La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 2007; 67:6253-6262.
173. Bahleda R, Soria J, Harbison C, Park J, Felip E, Hanna N, et al. Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. J Clin Oncol 2009; 27 (Suppl):S15.
174. Schiller JH, Larson T, Ou SI, Limentani SA, Sandler AB, Vokes EE, et al. Efficacy and safety of axitinib in patients with advanced non-small cell lung cancer: results from a phase II study. J Clin Oncol 2009; 27:3836-3841.
175. Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 2008; 9:1324-1335.
176. Altorki N, Guarino M, Lee P, Pass HI, Filip E, Bauer T, et al. Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): a proof-ofconcept study [abstr 8557]. J Clin Oncol 2008; 26 (Suppl).
177. Tortora G, Ciardiello F, Gasparini G. Combined targeting of EGFRdependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol 2008; 5:521-530.
178. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancer. J Clin Oncol 2005; 23:2544-2555.
179. Groen HJ, Smit EF, Dingemans A. A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25 (Suppl):S18.
180. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007; 25:4743-4750.
181. Hainsworth J, Herbst R. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (avastin) in combination with erlotinib (tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA). J Thorac Oncol 2008; 3 (Suppl):S302.
182. Miller VA, O'Connor P, Soh C, Kabbinavar F. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27 (Suppl):S18.
183. Johnson B, Miller V, Amier L, Stern H, Soh C, O'Connor P, et al. Biomarker evaluation in the randomized, double-blind, placebo-controlled, phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Presented at 34th ESMO Multidisciplinary Congress, 2009, abstract 8LBA.
184. Lind JS, Dingemans AC, Groen HJ, Smit EF. A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/ metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27 (Suppl):S15.
185. Gandara D, Kim ES, Herbst RS, Moon J, Redman MW, Dakhil SR, et al. S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): a SWOG phase II study. J Clin Oncol 2009; 27 (Suppl):S1.